Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Microbot Medical Inc.NASDAQ: MBOT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$3.66M, compared with -$2.59M a year earlier. Trailing-twelve-month EBITDA was -$14.17M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -15.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.66M-5.9% QoQ
- Last fiscal yearDec 2025
- -$13.1M-15.4% YoY
- LTMMar 2026
- -$14.17M-22.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -41.5% | +100.0% | +141.5 pp |
| 1 year | -15.4% | +100.0% | +115.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (13.1M) USD
- Year-over-year change
- -15.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (13.1M) | -15.4% |
| FY2024 | 2024-12-31 | (11.35M) | -6.8% |
| FY2023 | 2023-12-31 | (10.63M) | +20.3% |
| FY2022 | 2022-12-31 | (13.34M) | -18.7% |
| FY2021 | 2021-12-31 | (11.24M) | — |
EBITDA vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -22.2% is the 8th highest of 10, against a peer median of -14.1%.
- EBITDA amounts to 13493.3% of revenue for MBOT, versus a peer median of 337.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.84M USD | +1391.3% | — | — | |
| LTM Mar 2026 | -CA$9.7M CAD | -3.8% | — | 5840.5% | |
| LTM Mar 2026 | -$14.17M USD | -22.2% | — | 13493.3% | |
| LTM Mar 2026 | -$24M USD | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$26.64M USD | -14.1% | — | — | |
| LTM Mar 2026 | -$29.2M USD | -21.6% | — | 21792.5% | |
| LTM Mar 2026 | -CA$36.27M CAD | -16.2% | — | — | |
| LTM Mar 2026 | -$37.72M USD | +25.1% | — | 52.1% | |
| LTM Mar 2026 | -$40.18M USD | -45.5% | — | — | |
| LTM Mar 2026 | -$156.43M USD | -1199.8% | — | 51.8% | |
| Peer median (excluding MBOT) | — | -14.1% | — | 337.0% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 106K | 91K | 0 |
| Gross Profit | 0 | 0 | (106K) | (91K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.15M | 7.74M | 5.72M | 6.63M | 6.28M |
| Selling, General & Admin | 5.41M | 5.58M | 4.13M | 5M | 8.25M |
| Operating Expenses | 11.36M | 13.28M | 9.75M | 11.53M | 14.74M |
| Depreciation & Amortization | 76K | 102K | 106K | 91K | 47K |
| EBITDA | (11.24M) | (13.34M) | (10.63M) | (11.35M) | (13.1M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (11.36M) | (13.28M) | (9.86M) | (11.63M) | (14.74M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 44K | 54K | 228K | 182K | 1.29M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 44K | 113K | (885K) | 182K | 1.6M |
| Income Before Tax | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (11.31M) | (13.17M) | (10.74M) | (11.44M) | (13.14M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.59) | (1.81) | (1.05) | (0.73) | (0.29) |
| EPS (Diluted) | (1.59) | (1.81) | (1.05) | (0.73) | (0.29) |
| Weighted Avg Shares | 7.11M | 7.26M | 10.2M | 15.65M | 45.79M |
| Weighted Avg Shares (Diluted) | 7.11M | 7.26M | 10.2M | 15.65M | 45.79M |
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.